Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Oric Pharmaceuticals (ORIC)
NASDAQ:ORIC
RESEARCH TOOLSreports
Holding ORIC?
Track your performance easily
ORIC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.33 - $16.65
Previous Close$9.59
Volume663.22K
Average Volume (3M)447.69K
Market Cap
$676.74M
Enterprise Value$404.37M
Total Cash (Recent Filing)$272.37M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.90
Next Earnings
Mar 25, 2025EPS Estimate
-$0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.81
Shares Outstanding70,566,950
10 Day Avg. Volume435,315
30 Day Avg. Volume447,695
Standard Deviation0.25
R-Squared0.05
Alpha-0.00539
Financial Highlights & Ratios
Price to Book (P/B)2.25
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-5.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-3.27
Forecast
1Y Price Target
$18.83Price Target Upside90.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Oric Pharmaceuticals News
PremiumCompany Announcements
Oric Pharmaceuticals Reports Strong Financial Growth and Clinical Progress
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentORIC is targeting difficult to treat NSCLC patients with high unmet need and showed promising initial efficacy and safety.
Financial OutlookWith 12+ months of cash, an experienced management team, and several data updates expected, the analyst is initiating on ORIC with a BUY rating and $17 PT.
Management And StrategyORIC has a highly experienced management team with a successful track record developing entrectinib at Ignyta, receiving tumor agnostic label in genetically defined cancers.
Bears Say
Clinical Development RiskInability to advance ORIC-114 and ORIC-944 in clinical development is a potential risk.
Clinical ValidationEED inhibition lacks clinical validation compared to EZH2 inhibitors, which have had mixed results.
Pipeline PerformanceNegative clinical data with pipeline candidates could impact the stock adversely.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ORIC FAQ
What was Oric Pharmaceuticals’s price range in the past 12 months?
Oric Pharmaceuticals lowest stock price was $6.33 and its highest was $16.65 in the past 12 months.
What is Oric Pharmaceuticals’s market cap?
Currently, no data Available
When is Oric Pharmaceuticals’s upcoming earnings report date?
Oric Pharmaceuticals’s upcoming earnings report date is Mar 25, 2025 which is in 119 days.
How were Oric Pharmaceuticals’s earnings last quarter?
Oric Pharmaceuticals released its earnings results on Nov 12, 2024. The company reported -$0.49 earnings per share for the quarter, missing the consensus estimate of -$0.478 by -$0.012.
Is Oric Pharmaceuticals overvalued?
According to Wall Street analysts Oric Pharmaceuticals’s price is currently Undervalued.
Does Oric Pharmaceuticals pay dividends?
Oric Pharmaceuticals does not currently pay dividends.
What is Oric Pharmaceuticals’s EPS estimate?
Oric Pharmaceuticals’s EPS estimate is -$0.5.
How many shares outstanding does Oric Pharmaceuticals have?
Oric Pharmaceuticals has 70,566,950 shares outstanding.
What happened to Oric Pharmaceuticals’s price movement after its last earnings report?
Oric Pharmaceuticals reported an EPS of -$0.49 in its last earnings report, missing expectations of -$0.478. Following the earnings report the stock price went up 0.097%.
Which hedge fund is a major shareholder of Oric Pharmaceuticals?
Among the largest hedge funds holding Oric Pharmaceuticals’s share is Viking Global Investors LP. It holds Oric Pharmaceuticals’s shares valued at 41M.
---
Oric Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.83 (90.78% Upside)
$18.83 (90.78% Upside)
Blogger Sentiment
Bullish
ORIC Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 82.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.3%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
31.36%
12-Months-Change
Fundamentals
Return on Equity
-45.98%
Trailing 12-Months
Asset Growth
10.11%
Trailing 12-Months
Company Description
Oric Pharmaceuticals
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely, ORIC-101 and ORIC-533.
---
ORIC Stock 12 Month Forecast
Average Price Target
$18.83
▲(90.78% Upside)
Technical Analysis
Best Analysts Covering ORIC
1 Year
1 Year Success Rate
6/9 ratings generated profit
1 Year Average Return
+9.39%
reiterated a buy rating 7 months ago
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +9.39% per trade.
---